Eva‐Maria Grischke
Universitätsklinikum Tübingen(DE)Institut für Frauengesundheit(DE)Universitäts Frauenklinik(DE)University Children's Hospital Tübingen(DE)University of Tübingen(DE)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Ovarian cancer diagnosis and treatment, Advanced Breast Cancer Therapies, BRCA gene mutations in cancer
Most-Cited Works
- → PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer(2016)30,895 cited
- → Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer(2016)1,957 cited
- → Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer(2004)1,701 cited
- → MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy(2017)1,620 cited
- → The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2(2019)960 cited
- → Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study